Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine.
The results of a double-blind clinical trial of fengabine vs clomipramine in depressed outpatients are reported. Fengabine, a new GABAergic agent, seems to be as effective as the reference drug, with a faster onset of action and a more marked effect on cognitive disturbances and retardation. The new drug is free of any significant anticholinergic or cardiovascular effect, and it is not sedative.
Nielsen
N P
NP
Department of Mental Health, Consultative Psychiatric Services, Como, Italy.
Cesana
B
B
Zizolfi
S
S
Ascalone
V
V
Priore
P
P
Morselli
P L
PL
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002733:Chlorophenols / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D002733:Chlorophenols; D002997:Clomipramine; C052028:fengabine